Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
Experience in the treatment of patients with acute promyelocytic leukaemia (APL) and accelerated phase chronic myeloid leukaemia with orally administered arsenic trioxide (ATO) in our institution since 1999 has demonstrated that bioavailability of oral ATO is comparable with intravenous administration, and similar outcomes are produced in treatment of APL. Oral administration was well tolerated, with good compliance, in patients not requiring hospitalisation for postinduction treatment and was particularly convenient for patients living considerable distances from our institution. Orally administered ATO can be considered a practicable option in management of APL.